Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

NCT00282100 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: Gefetinib (Iressa)

Sponsor

Tan Tock Seng Hospital

Collaborators

[object Object]
[object Object]